Best health care companies in San Diego, CA

NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market. NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess , a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF , NuVasive has built an entire spine franchise. With over 80 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness .

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, CA. Arena Pharmaceuticals is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility.

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin , MabThera , immunoglobulin, Cinryze and alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need.

Illumina is dedicated to advancing human health by unlocking the power of the genome. The company provides sequencing and array-based solutions for genetic analysis, and serve as tools for disease research, drug development, and the development of molecular tests in the clinic. Illumina's solutions are used in the life sciences, oncology, reproductive health, agriculture, forensic genomics, and other areas. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California. The company employs over 6000 employees.

MatrixCare is the complete solution for growing organizations that need to successfully manage risk in care delivery across the LTPAC spectrum. Trusted by more than 13,000 facility-based care settings and more than 2,500 home care, home health and hospice organizations, MatrixCare's solutions help ACOs, skilled nursing and senior living providers, life plan communities (CCRCs), and home health organizations to connect, collaborate and prosper as they migrate to a fee-for-value healthcare system.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity's vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.

Since 1999, Dexcom, Inc. has been transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. From inception, Dexcom has focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class--while empowering the community to take control of diabetes.

Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.

The mission of the San Ysidro Health Center (SYHC) is “to improve the health and well-being of our community's traditionally underserved and culturally diverse people.” SYHC is committed to providing the highest quality, compassionate, easily accessib...

Aya Healthcare is a leading provider of healthcare staffing, servicing over 1,400 healthcare facilities in the United States. The company recruits nurses and allied health professionals nationally and internationally and places them in travel nursing, per diem nursing and permanent nursing positions throughout the United States.

Call us to begin your exclusive Westmont Living experience. Our 55+ apartments are carefully designed to let you lead an active, independent lifestyle.

CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Formerly known as CannaVest, CV Sciences, Inc. has relaunched in 2016 as a life sciences organization, focused on promoting healthy living through their pharmaceutical drug development efforts and portfolio of finished product brands. Makers of PlusCBD Oil, the leading brand in hemp-derived CBD oil products available online, in health food stores, and practitioners offices nationwide.

Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs. Develops a line of diagnostic and therapeutic products for diabetics. Working towards a cure for diabetes by challenging science, changing lives. Amylin employees are dedicated in their ability to "think outside the box". Because of our commitment of constantly finding newer and better ways to treat diabetes, we come to work each day feeling like we CAN make a difference in our world.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.